journal article·2011-01

Evaluation of the impact of arginine–chitosan/DNA nanoparticles on human naive CD4+ T cells

Lanxia Liu, Yuanyuan Bai, Dunwan Zhu, Liping Song, Hai Wang, Xia Dong, Hailing Zhang, Xigang Leng

Publisher page

Abstract

Abstract Previous studies showed that arginine‐conjugated chitosan (ACS)/DNA nanoparticles (ACGN) mediated significantly higher expression of the transgenes when compared with chitosan (CS)/DNA nanoparticles (CGN). However, the interactions between ACGN and immune cells still remain poorly understood. The present study investigated whether ACGN affected the initial differentiation direction of human naive CD4+ T cells, either directly or indirectly. It was demonstrated that both ACGN and CGN induced slightly higher production of IL‐12 by THP‐1 cells in the order of ACGN > CGN. However, this macrophage stimulating activity was much less significant when compared with lipopolysaccharide and did not impact on the differentiation of the naive CD4+ T cells separated from the nanoparticles and THP‐1 cells by a 0.1‐μm diameter polycarbonate semipermeable membrane, which allows the pass through of macromolecules including IL‐12. It also demonstrated that, when directly exposed to naive CD4+ T cells, none of the nanoparticles induced either the activation of the naive CD4+ T cells in the absence of recombinant human IL‐4 (rhIL‐4) or IFN‐γ (rhIFN‐γ) that induce naive CD4+ T cell polarization or any changes in the differentiation direction of the naive CD4+ T cells in the presence of the corresponding cytokines. © 2010 Wiley Periodicals, Inc. J Biomed Mater Res Part A, 2010.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Immune Response and Inflammation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (35)

Show source-provided references
1. 10.1016/S0959-440X(96)80052-210.1016/S0959-440X(96)80052-2 ↗
2. 10.1016/S0168-3659(98)00097-210.1016/S0168-3659(98)00097-2 ↗
3. 10.1016/S0378-5173(98)00378-010.1016/S0378-5173(98)00378-0 ↗
4. 10.1016/S0168-3659(00)00361-810.1016/S0168-3659(00)00361-8 ↗
5. 10.1023/A:101198100067110.1023/A:1011981000671 ↗
6. 10.1016/S0142-9612(02)00507-010.1016/S0142-9612(02)00507-0 ↗
7. 10.1016/S0168-3659(02)00144-X10.1016/S0168-3659(02)00144-X ↗
8. 10.1016/j.jconrel.2004.08.01010.1016/j.jconrel.2004.08.010 ↗
9. 10.1016/S0939-6411(03)00155-310.1016/S0939-6411(03)00155-3 ↗
10. 10.1016/j.jconrel.2004.10.01810.1016/j.jconrel.2004.10.018 ↗
11. 10.1038/sj.mt.630017210.1038/sj.mt.6300172 ↗
12. 10.1529/biophysj.103.03402510.1529/biophysj.103.034025 ↗
13. 10.1128/JVI.79.18.11864-11872.200510.1128/JVI.79.18.11864-11872.2005 ↗
14. 10.1517/17425247.3.2.17710.1517/17425247.3.2.177 ↗
15. 10.1074/jbc.M21189120010.1074/jbc.M211891200 ↗
16. 10.1038/sj.gt.330218310.1038/sj.gt.3302183 ↗
17. 10.1007/s11434-007-0455-y10.1007/s11434-007-0455-y ↗
18. 10.1007/s11051-009-9722-y10.1007/s11051-009-9722-y ↗
19. 10.1016/j.molmed.2009.03.00210.1016/j.molmed.2009.03.002 ↗
20. 10.1038/ni125410.1038/ni1254 ↗
21. 10.1038/nature0475310.1038/nature04753 ↗
22. 10.1182/blood-2007-11-12099810.1182/blood-2007-11-120998 ↗
23. 10.1016/j.immuni.2008.05.00710.1016/j.immuni.2008.05.007 ↗
24. 10.1038/nature0475410.1038/nature04754 ↗
25. 10.1007/s10856-008-3621-010.1007/s10856-008-3621-0 ↗
26. 10.1016/S1359-6101(03)00043-110.1016/S1359-6101(03)00043-1 ↗
27. 10.1189/jlb.110463110.1189/jlb.1104631 ↗
28. 10.1016/S0264-410X(00)00248-610.1016/S0264-410X(00)00248-6 ↗
29. 10.1016/j.vaccine.2003.09.04410.1016/j.vaccine.2003.09.044 ↗
30. 10.1016/j.imbio.2008.07.00710.1016/j.imbio.2008.07.007 ↗
31. 10.1016/j.biomaterials.2004.04.00610.1016/j.biomaterials.2004.04.006 ↗
32. 10.1016/j.bbrc.2003.09.13410.1016/j.bbrc.2003.09.134 ↗
33. 10.4049/jimmunol.171.1.21210.4049/jimmunol.171.1.212 ↗
34. 10.1016/S0145-305X(02)00104-010.1016/S0145-305X(02)00104-0 ↗
35. 10.1038/nnano.2007.22310.1038/nnano.2007.223 ↗